2025-12-31 - Analysis Report
Okay, here's a comprehensive analysis of TG Therapeutics (TGTX) based on the provided data:

**0) Report Structure:**

This report will first present the raw data for each section. Following the data, a simple analysis will be provided for that section. Finally, a comprehensive summary will combine the findings for an overall investment perspective.

**1) Return Rate Comparison:**

*   **Ticker:** TGTX
*   **Company Overview:** TG Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
*   **TGTX Cumulative Return:** 65.26%
*   **VOO (S&P 500) Cumulative Return:** 102.21%
*   **Divergence:**
    *   Current: -32.3
    *   Relative Divergence: 16.9

**Analysis:**

TGTX has underperformed the S&P 500 (VOO) significantly.  The cumulative return is much lower.  The divergence of -32.3 indicates underperformance. The relative divergence of 16.9 suggests the current divergence is near the low end of its historical range compared to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha    | Beta   | Cap(B) |
|------------|---------|-------|----------|--------|--------|
| 2015-2017  | -5.0%   | 73.5% | -33.0%   | -0.0   | 1.3    |
| 2016-2018  | -12.0%  | 73.5% | -27.0%   | -0.0   | 0.7    |
| 2017-2019  | 74.0%   | 74.1% | 52.0%    | 0.0    | 1.8    |
| 2018-2020  | 316.0%  | 74.1% | 293.0%   | 0.1    | 8.3    |
| 2019-2021  | 124.0%  | 74.1% | 78.0%    | 0.3    | 3.0    |
| 2020-2022  | -71.0%  | 77.8% | -71.0%   | -0.0   | 1.9    |
| 2021-2023  | -284.0% | 77.8% | -285.0%  | -1.1   | 2.7    |
| 2022-2024  | 56.0%   | 77.8% | 36.0%    | -1.0   | 4.8    |
| 2023-2025  | 66.0%   | 80.7% | -1.0%    | -0.1   | 4.7    |

**Analysis:**

*   **CAGR:**  Highly volatile, with periods of substantial gains (2018-2020) and significant losses (2021-2023).
*   **MDD:**  High Maximum Drawdown consistently around 73-80%, indicating significant risk.
*   **Alpha:**  Generally positive alpha during periods of strong growth but negative alpha during downturns, indicating the stock's performance is tied to its own specific factors rather than just market movement.
*   **Beta:**  Low Beta values suggest that the price of TGTX is not very correlated with the market (S&P500).

**2) Recent Stock Price Fluctuations:**

*   **Close:** 29.75
*   **Last-market:** {'price': 29.75, 'previousClose': 30.53, 'change': -2.55}
*   **5-day SMA:** 30.57
*   **20-day SMA:** 30.89
*   **60-day SMA:** 32.48

**Analysis:**

The stock price is currently below all three moving averages (5, 20, and 60-day). This suggests a short-term downtrend. The recent price decrease (change: -2.55) indicates some selling pressure.

**3) RSI, PPO, and Expected Return:**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 45.57
*   **PPO:** -0.0887
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (32 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** 0.1 (+) indicating short-term upward trend.
*   **Expected Return (%):** -134.8%

**Analysis:**

*   **MRI:** The high MRI suggests the model believes TGTX is a good investment from a risk/reward perspective.
*   **RSI:** The RSI is at 45.57, which is neutral (not overbought or oversold).
*   **PPO:**  The negative PPO suggests a downtrend in momentum.
*   **Hybrid Signal:** The Hybrid Signal advises buying, reinforcing the positive MRI.
*   **Expected Return:**  The extremely negative expected return is a significant red flag. This suggests that even if the model recommends buying now, the potential future returns are expected to be very poor.
* The divergence change indicates short-term upward trend.

**4) Recent News & Significant Events:**

*   **[2025-12-30]** TG Therapeutics: What Wall Street Isn't Telling You (Seeking Alpha)
*   **[2025-12-28]** Investing in TG Therapeutics (NASDAQ:TGTX) three years ago would have delivered you a 160% gain (Yahoo Finance)
*   **[2025-12-29]** Could The Market Be Wrong About TG Therapeutics, Inc. (NASDAQ:TGTX) Given Its Attractive Financial Prospects? (simplywall.st)
*   **[2025-11-03]** The Earnings Caveat That Sent This Hot Biotech Diving (Investor's Business Daily)
*   **[2025-12-26]** TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Recommendation of "Moderate Buy" from Brokerages (MarketBeat)
*   **[2025-10-31]** TG Therapeutics (NASDAQ: TGTX) schedules Q3 results call, 8:30 a.m. ET, business update (Stock Titan)

**Analysis:**

The news headlines present a mixed picture. Some articles highlight past gains and potential undervaluation ("Could The Market Be Wrong?"), while others point to negative earnings catalysts ("Earnings Caveat That Sent This Hot Biotech Diving").  The overall sentiment seems cautiously optimistic, with a "Moderate Buy" recommendation on average.

**4-2) Analyst Opinions:**

*   **Mean Recommendation:** Not Available
*   **Opinions:** 7
*   **Target Price (avg/high/low):** 44.29 / 60.00 / 13.00
*   **Recent Rating Changes:** No changes are available

**Analysis:**

The analyst target prices suggest potential upside, with an average target significantly above the current price. However, the large range between the high and low targets indicates uncertainty among analysts.

**5) Recent Earnings Analysis:**

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-11-05 | 2.69 | 0.16 B$    |
| 2025-08-08 | 0.19 | 0.14 B$    |
| 2025-05-09 | 0.03 | 0.12 B$    |
| 2024-11-07 | 0.03 | 0.08 B$    |
| 2025-11-05 | 0.03 | 0.08 B$    |

**Analysis:**

* Revenue increased gradually over the periods shown.
* EPS showed dramatic increased on 2025-11-05. It is an anomality among the quarters.

**6) Financial Information:**

Revenue and Profitability:

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-09-30   | $0.16B  | 82.63%        |
| 2025-06-30   | $0.14B  | 86.58%        |
| 2025-03-31   | $0.12B  | 87.14%        |
| 2024-12-31   | $0.11B  | 85.77%        |
| 2024-09-30   | $0.08B  | 88.86%        |

Capital and Profitability:

| Quarter      | Equity  | ROE    |
|--------------|---------|--------|
| 2025-09-30   | $0.61B  | 64.37% |
| 2025-06-30   | $0.28B  | 10.20% |
| 2025-03-31   | $0.24B  | 2.13%  |
| 2024-12-31   | $0.22B  | 10.49% |
| 2024-09-30   | $0.19B  | 2.02%  |

**Analysis:**

*   **Revenue:** Revenue has generally increased over the past few quarters.
*   **Profit Margin:** Profit margins are exceptionally high, suggesting strong pricing power or cost management.
*   **Equity:** Equity has increased significantly, particularly in the most recent quarter.
*   **ROE:** ROE is very volatile, with a dramatic spike in the most recent quarter. This spike warrants further investigation to understand its sustainability.

**7) Comprehensive Analysis (Summary):**

*   **Performance:** TGTX has significantly underperformed the S&P 500. Historical performance is highly volatile.
*   **Risk:** The stock exhibits high Maximum Drawdown, indicating a high-risk investment.
*   **Technical Indicators:** Current price action is bearish, with the price below key moving averages and a negative PPO. The MRI is bullish, but the Expected Return is severely negative.
*   **News & Sentiment:** News headlines are mixed, with both positive and negative catalysts. Analyst opinions are varied, but the average target price suggests upside.
*   **Financials:** Revenue and profit margins are strong. The recent EPS, equity, and ROE spikes require further investigation.
*   **Overall:**

    **Recommendation:**  The data presents a conflicted picture. The high MRI, analyst price targets, and the recent uptrend in relative divergence suggest potential short-term gains.

    However, the negative Expected Return and high historical volatility, coupled with the significant underperformance compared to the S&P 500, suggest a **high-risk** investment. The data warrants caution. Further investigation is needed to determine the reason for the negative expected return and the sustainability of the recent financial improvements.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.